Product Description
Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896668/)
Mechanisms of Action: Serum Albumin Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Small Cell Lung Cancer|Sarcoma|Glioblastoma|Pancreatic Cancer|Sarcoma, Kaposi|Adenocarcinoma|HIV Seropositivity|Pancreatic Ductal Carcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ALDOXORUBICIN-P1/2-STS-03 | P2 |
Completed |
Sarcoma |
2018-05-01 |
|
| ALDOXORUBICIN-P2-SCLC-01 | P2 |
Completed |
Small Cell Lung Cancer |
2017-05-15 |
|
| 2013-004103-40 | P3 |
Completed |
Sarcoma |
2017-05-15 |
|
| ALDOXORUBICIN-P3-STS-01 | P3 |
Completed |
Sarcoma |
2017-05-01 |